Cabozantinib malate (XL184)
≥99%
- Product Code: 67546
CAS:
1140909-48-3
| Molecular Weight: | 635.60 g./mol | Molecular Formula: | C₂₈H₂₄FN₃O₅C₄H₆O₅ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | Room temperature, dry, sealed |
Product Description:
Cabozantinib malate is primarily used in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It is also effective in managing progressive, metastatic medullary thyroid cancer (MTC). The drug works by inhibiting multiple tyrosine kinases, which are involved in tumor growth, angiogenesis, and metastasis. This makes it a valuable option for patients who have not responded well to other therapies. Additionally, cabozantinib malate is being investigated for its potential in treating other cancers, such as hepatocellular carcinoma and certain forms of prostate cancer, due to its ability to target specific pathways involved in cancer progression.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White to off-white powder |
| PURITY | 98.5-100 |
| WATER | 0.5 % |
| RESIDUE ON IGNITION | 0 0.1 % |
| heavy metals | 0 20 ppm |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.010 | 10-20 days | £15.38 |
+
-
|
| 0.050 | 10-20 days | £31.21 |
+
-
|
| 0.100 | 10-20 days | £47.50 |
+
-
|
| 0.250 | 10-20 days | £95.67 |
+
-
|
| 1.000 | 10-20 days | £248.79 |
+
-
|
| 5.000 | 10-20 days | £771.24 |
+
-
|
Cabozantinib malate (XL184)
Cabozantinib malate is primarily used in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It is also effective in managing progressive, metastatic medullary thyroid cancer (MTC). The drug works by inhibiting multiple tyrosine kinases, which are involved in tumor growth, angiogenesis, and metastasis. This makes it a valuable option for patients who have not responded well to other therapies. Additionally, cabozantinib malate is being investigated for its potential in treating other cancers, such as hepatocellular carcinoma and certain forms of prostate cancer, due to its ability to target specific pathways involved in cancer progression.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
£0.00
£0.00
Total :